Compugen Third Quarter 2011 Conference Call Scheduled for Tuesday, November 8, 2011 at 10:00 AM EST
24 Octubre 2011 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM EST on Tuesday, November 8,
2011 to review third quarter 2011 results. The quarterly results
will be released on the Company’s website (www.cgen.com), prior to
the conference call.
To access the conference call, please dial 1-888-668-9141 from
the US, or +972-3-918-0609 internationally. The call will also be
available via live webcast through Compugen’s website, located at
the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-295-2634 from the US or
+972-3-925-5921 internationally. The replay will be available
through November 11, 2011.
About Compugen
Compugen is a leading therapeutic product candidate discovery
company, currently focused on biologics-based therapy to address
important unmet needs in the fields of immunology and oncology,
either for Compugen or its partners. Unlike traditional high
throughput trial and error experimental based drug candidate
discovery, Compugen’s discovery efforts are based on systematic and
continuously improving in silico (by computer) product candidate
prediction and selection followed by experimental validation, with
selected product candidates being advanced in its Pipeline Program
to the pre-IND stage. Compugen’s in silico predictive models
utilize a broad and continuously growing infrastructure of
proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities. The Company’s business model primarily
involves collaborations covering the further development and
commercialization of Compugen-discovered product candidates and
various forms of “discovery on demand” arrangements, in both cases
providing Compugen with potential milestone payments and royalties
on product sales or other forms of revenue sharing. In 2002,
Compugen established an affiliate, Evogene Ltd. (www.evogene.com)
(TASE: EVGN.TA), to utilize certain of the Company's in silico
predictive discovery capabilities in agricultural biotechnology.
For additional information, please visit Compugen's corporate
website at www.cgen.com.
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as "may," "expects,"
"anticipates," "believes," and "intends," and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
identified and more fully explained under the heading "Risk
Factors" in Compugen's annual reports filed with the Securities and
Exchange Commission.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024